First Manhattan’s DiaMedica Therapeutics DMAC Stock Holding History

First Manhattan’s Portfolio DMAC Stock Details DMAC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-455,000	Closed	-$3.08M	–	761
2026 Q1	$3.08M	Buy	455,000 +50,000	+12%	+$396K	0.01%	293
2025 Q4	$3.22M	Sell	405,000 -100,000	-20%	-$748K	0.01%	282
2025 Q3	$3.47M	Sell	505,000 -101,435	-17%	-$550K	0.01%	274
2025 Q2	$2.37M	Hold	606,435	–	–	0.01%	311
2025 Q1	$2.3M	Sell	606,435 -232,646	-28%	-$1.33M	0.01%	285
2024 Q4	$4.56M	Hold	839,081	–	–	0.01%	224
2024 Q3	$3.52M	Hold	839,081	–	–	0.01%	248
2024 Q2	$2.48M	Sell	839,081 -10,957	-1%	-$30.1K	0.01%	275
2024 Q1	$2.35M	Buy	850,038 +735,294	+641%	+$2.13M	0.01%	283
2023 Q4	$326K	Hold	114,744	–	–	﹤0.01%	551
2023 Q3	$296K	Sell	114,744 -10,000	-8%	-$32.1K	﹤0.01%	581
2023 Q2	$539K	Buy	+124,744	New	+$303K	﹤0.01%	470

Other funds holding DMAC

CLG

Cooperman Leon G $3.55B AUM 41.85% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Bleichroeder LP New York $559M AUM 83.7% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

First Manhattan's DMAC Position: Q2 2026 in Review

First Manhattan sold out of DiaMedica Therapeutics (DMAC) in Q2 2026, closing a stake of 455,000 shares — an estimated $3.08M sold.

First Manhattan first reported a position in DMAC in Q2 2023 and held it in 12 quarters. The position peaked at $4.56M in Q4 2024. 89 funds tracked by Wall St. Rank hold DMAC as of Q2 2026.

First Manhattan reported no remaining DiaMedica Therapeutics position as of Q2 2026 after selling out during the quarter.
First Manhattan sold 455,000 DiaMedica Therapeutics shares in Q2 2026, an estimated $3.08M.
First Manhattan first reported a position in DiaMedica Therapeutics in Q2 2023 and held it in 12 quarters.
First Manhattan's DiaMedica Therapeutics position peaked at $4.56M in Q4 2024.
89 funds tracked by Wall St. Rank held DiaMedica Therapeutics as of Q2 2026.

Based on First Manhattan's 13F filing for Q2 2026, filed 14 Aug 2026.